Celldex Therapeutics Net Worth
Celldex Therapeutics Net Worth Breakdown | CLDX |
Celldex Therapeutics Net Worth Analysis
Celldex Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Celldex Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Celldex Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Celldex Therapeutics' net worth analysis. One common approach is to calculate Celldex Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Celldex Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Celldex Therapeutics' net worth. This approach calculates the present value of Celldex Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Celldex Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Celldex Therapeutics' net worth. This involves comparing Celldex Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Celldex Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Celldex Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Celldex Therapeutics' net worth research are outlined below:
| Celldex Therapeutics generated a negative expected return over the last 90 days | |
| Celldex Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 6.88 M. Net Loss for the year was (141.43 M) with loss before overhead, payroll, taxes, and interest of (137.06 M). | |
| Celldex Therapeutics currently holds about 356.82 M in cash with (107.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.63. | |
| Celldex Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: When Moves Investors should Listen - Stock Traders Daily |
Celldex Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Celldex Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Celldex Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Celldex Therapeutics Target Price Consensus
Celldex target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Celldex Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 12 | Strong Buy |
Most Celldex analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Celldex stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Celldex Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationCelldex Therapeutics Target Price Projection
Celldex Therapeutics' current and average target prices are 23.78 and 67.10, respectively. The current price of Celldex Therapeutics is the price at which Celldex Therapeutics is currently trading. On the other hand, Celldex Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Celldex Therapeutics Market Quote on 18th of January 2025
Target Price
Analyst Consensus On Celldex Therapeutics Target Price
Know Celldex Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Celldex Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Celldex Therapeutics backward and forwards among themselves. Celldex Therapeutics' institutional investor refers to the entity that pools money to purchase Celldex Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Goldman Sachs Group Inc | 2024-09-30 | 1.8 M | T. Rowe Price Investment Management,inc. | 2024-09-30 | 1.7 M | Commodore Capital Lp | 2024-09-30 | 1.6 M | Point72 Asset Management, L.p. | 2024-09-30 | 1.6 M | Geode Capital Management, Llc | 2024-09-30 | 1.5 M | Jennison Associates Llc | 2024-09-30 | 1.3 M | Pictet Asset Manangement Sa | 2024-09-30 | 1.1 M | Rock Springs Capital Management Lp | 2024-09-30 | 1.1 M | Novo A/s | 2024-09-30 | 963.7 K | Wellington Management Company Llp | 2024-09-30 | 9.2 M | Fmr Inc | 2024-09-30 | 6 M |
Follow Celldex Therapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.51 B.Market Cap |
|
Project Celldex Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.37) | (0.39) | |
| Return On Capital Employed | (0.41) | (0.43) | |
| Return On Assets | (0.27) | (0.29) | |
| Return On Equity | (0.38) | (0.40) |
When accessing Celldex Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Celldex Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Celldex Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Celldex Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Celldex Therapeutics. Check Celldex Therapeutics' Beneish M Score to see the likelihood of Celldex Therapeutics' management manipulating its earnings.
Evaluate Celldex Therapeutics' management efficiency
Celldex Therapeutics has return on total asset (ROA) of (0.1973) % which means that it has lost $0.1973 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2984) %, meaning that it created substantial loss on money invested by shareholders. Celldex Therapeutics' management efficiency ratios could be used to measure how well Celldex Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.39 in 2025. Return On Capital Employed is likely to drop to -0.43 in 2025. At this time, Celldex Therapeutics' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 6.6 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 31 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 10.19 | 9.68 | |
| Tangible Book Value Per Share | 9.54 | 9.06 | |
| Enterprise Value Over EBITDA | (12.23) | (12.84) | |
| Price Book Value Ratio | 4.03 | 3.62 | |
| Enterprise Value Multiple | (12.23) | (12.84) | |
| Price Fair Value | 4.03 | 3.62 | |
| Enterprise Value | 1.7 B | 1.8 B |
Management at Celldex Therapeutics focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Enterprise Value Revenue 74.9594 | Revenue | Quarterly Revenue Growth 1.103 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Celldex Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Celldex Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Celldex Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Celldex Therapeutics Corporate Filings
F4 | 20th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 6th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 25th of April 2024 Other Reports | ViewVerify |
Celldex Therapeutics Earnings Estimation Breakdown
The calculation of Celldex Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Celldex Therapeutics is estimated to be -0.599725 with the future projection ranging from a low of -0.655 to a high of -0.5375. Please be aware that this consensus of annual earnings estimates for Celldex Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.66 Lowest | Expected EPS | -0.54 Highest |
Celldex Therapeutics Earnings Projection Consensus
Suppose the current estimates of Celldex Therapeutics' value are higher than the current market price of the Celldex Therapeutics stock. In this case, investors may conclude that Celldex Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Celldex Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 12 | 91.06% | -0.64 | -0.599725 | -2.6 |
Celldex Therapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of Celldex Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Celldex Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of Celldex Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Celldex Therapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Celldex Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Celldex Therapeutics should always be considered in relation to other companies to make a more educated investment decision.Celldex Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Celldex Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-10-31 | 2024-09-30 | -0.67 | -0.64 | 0.03 | 4 | ||
2024-08-08 | 2024-06-30 | -0.59 | -0.54 | 0.05 | 8 | ||
2024-05-06 | 2024-03-31 | -0.69 | -0.56 | 0.13 | 18 | ||
2024-02-26 | 2023-12-31 | -0.74 | -0.83 | -0.09 | 12 | ||
2023-11-02 | 2023-09-30 | -0.68 | -0.81 | -0.13 | 19 | ||
2023-08-08 | 2023-06-30 | -0.67 | -0.65 | 0.02 | 2 | ||
2023-05-04 | 2023-03-31 | -0.63 | -0.62 | 0.01 | 1 | ||
2023-02-28 | 2022-12-31 | -0.59 | -0.56 | 0.03 | 5 | ||
2022-11-09 | 2022-09-30 | -0.58 | -0.57 | 0.01 | 1 | ||
2022-08-08 | 2022-06-30 | -0.51 | -0.59 | -0.08 | 15 | ||
2022-05-05 | 2022-03-31 | -0.45 | -0.49 | -0.04 | 8 | ||
2022-02-28 | 2021-12-31 | -0.42 | -0.43 | -0.01 | 2 | ||
2021-11-09 | 2021-09-30 | -0.36 | -0.45 | -0.09 | 25 | ||
2021-08-05 | 2021-06-30 | -0.4 | -0.34 | 0.06 | 15 | ||
2021-05-06 | 2021-03-31 | -0.345 | -0.42 | -0.075 | 21 | ||
2021-03-29 | 2020-12-31 | -0.37 | -0.55 | -0.18 | 48 | ||
2020-11-05 | 2020-09-30 | -0.36 | -0.36 | 0.0 | 0 | ||
2020-08-06 | 2020-06-30 | -0.58 | -0.5 | 0.08 | 13 | ||
2020-05-06 | 2020-03-31 | -0.71 | -0.73 | -0.02 | 2 | ||
2020-03-26 | 2019-12-31 | -0.9 | -0.64 | 0.26 | 28 | ||
2019-11-12 | 2019-09-30 | -0.84 | -0.75 | 0.09 | 10 | ||
2019-08-07 | 2019-06-30 | -1.17 | -0.84 | 0.33 | 28 | ||
2019-05-07 | 2019-03-31 | -1.14 | -1.4 | -0.26 | 22 | ||
2019-03-07 | 2018-12-31 | -1.2 | -0.81 | 0.39 | 32 | ||
2018-11-07 | 2018-09-30 | -2.25 | -0.6 | 1.65 | 73 | ||
2018-08-08 | 2018-06-30 | -2.1 | -1.65 | 0.45 | 21 | ||
2018-05-10 | 2018-03-31 | -3.03 | -0.9 | 2.13 | 70 | ||
2018-03-07 | 2017-12-31 | -3.71 | -2.55 | 1.16 | 31 | ||
2017-11-07 | 2017-09-30 | -3.97 | -3.0 | 0.97 | 24 | ||
2017-08-08 | 2017-06-30 | -4.09 | -3.45 | 0.64 | 15 | ||
2017-05-09 | 2017-03-31 | -4.28 | -3.75 | 0.53 | 12 | ||
2017-03-14 | 2016-12-31 | -5.04 | -4.5 | 0.54 | 10 | ||
2016-11-07 | 2016-09-30 | -4.97 | -4.35 | 0.62 | 12 | ||
2016-08-08 | 2016-06-30 | -5.05 | -4.8 | 0.25 | 4 | ||
2016-05-05 | 2016-03-31 | -5.23 | -5.25 | -0.02 | 0 | ||
2016-02-23 | 2015-12-31 | -5.2 | -4.95 | 0.25 | 4 | ||
2015-11-05 | 2015-09-30 | -5.23 | -4.8 | 0.43 | 8 | ||
2015-08-10 | 2015-06-30 | -5.1 | -4.95 | 0.15 | 2 | ||
2015-04-29 | 2015-03-31 | -5.46 | -4.95 | 0.51 | 9 | ||
2015-02-24 | 2014-12-31 | -5.28 | -5.4 | -0.12 | 2 | ||
2014-11-05 | 2014-09-30 | -4.95 | -4.65 | 0.3 | 6 | ||
2014-08-06 | 2014-06-30 | -4.84 | -4.8 | 0.04 | 0 | ||
2014-05-01 | 2014-03-31 | -3.94 | -4.95 | -1.01 | 25 | ||
2014-03-03 | 2013-12-31 | -4.18 | -4.05 | 0.13 | 3 | ||
2013-11-08 | 2013-09-30 | -3.66 | -4.35 | -0.69 | 18 | ||
2013-08-06 | 2013-06-30 | -3.34 | -3.6 | -0.26 | 7 | ||
2013-05-02 | 2013-03-31 | -3.3 | -3.45 | -0.15 | 4 | ||
2013-03-07 | 2012-12-31 | -3.75 | -4.05 | -0.3 | 8 | ||
2012-11-01 | 2012-09-30 | -3.62 | -3.75 | -0.13 | 3 | ||
2012-08-10 | 2012-06-30 | -3.79 | -3.45 | 0.34 | 8 | ||
2012-05-03 | 2012-03-31 | -3.57 | -4.05 | -0.48 | 13 | ||
2012-03-07 | 2011-12-31 | -4.17 | -4.35 | -0.18 | 4 | ||
2011-11-02 | 2011-09-30 | -3.84 | -4.05 | -0.21 | 5 | ||
2011-08-03 | 2011-06-30 | -4.29 | -4.05 | 0.24 | 5 | ||
2011-05-04 | 2011-03-31 | -4.54 | -4.65 | -0.11 | 2 | ||
2011-03-03 | 2010-12-31 | 3.15 | -3.6 | -6.75 | 214 | ||
2010-11-02 | 2010-09-30 | -4.87 | -4.35 | 0.52 | 10 | ||
2010-08-04 | 2010-06-30 | -3.95 | -4.5 | -0.55 | 13 | ||
2010-05-04 | 2010-03-31 | -3.95 | -3.15 | 0.8 | 20 | ||
2010-03-04 | 2009-12-31 | -4.3 | -6.45 | -2.15 | 50 | ||
2009-11-04 | 2009-09-30 | -8.32 | -6.75 | 1.57 | 18 | ||
2009-08-05 | 2009-06-30 | -7.1 | -8.25 | -1.15 | 16 | ||
2009-05-05 | 2009-03-31 | -6.9 | -7.35 | -0.45 | 6 | ||
2009-02-27 | 2008-12-31 | -8.1 | -7.05 | 1.05 | 12 | ||
2008-11-05 | 2008-09-30 | -7.2 | -7.5 | -0.3 | 4 | ||
2008-08-06 | 2008-06-30 | -8.4 | -10.05 | -1.65 | 19 | ||
2008-05-19 | 2008-03-31 | -9.97 | -32.85 | -22.88 | 229 | ||
2007-10-31 | 2007-09-30 | -12.6 | -12.6 | 0.0 | 0 | ||
2007-08-02 | 2007-06-30 | -18 | -12.6 | 5.4 | 30 | ||
2007-05-03 | 2007-03-31 | -14.4 | -12.6 | 1.8 | 12 | ||
2007-03-07 | 2006-12-31 | -14.4 | -14.4 | 0.0 | 0 | ||
2006-11-01 | 2006-09-30 | -12.6 | -14.4 | -1.8 | 14 | ||
2006-08-02 | 2006-06-30 | -12.6 | -14.4 | -1.8 | 14 | ||
2006-05-09 | 2006-03-31 | -5.4 | -7.2 | -1.8 | 33 | ||
2006-03-08 | 2005-12-31 | -10.8 | -9.0 | 1.8 | 16 | ||
2005-10-27 | 2005-09-30 | -12.6 | -10.8 | 1.8 | 14 | ||
2005-08-03 | 2005-06-30 | -6.3 | -10.8 | -4.5 | 71 | ||
2005-05-05 | 2005-03-31 | -11.7 | -12.6 | -0.9 | 7 | ||
2005-03-02 | 2004-12-31 | -10.8 | -9.0 | 1.8 | 16 | ||
2004-07-22 | 2004-06-30 | -9 | -9.0 | 0.0 | 0 | ||
2004-04-21 | 2004-03-31 | -9 | -5.4 | 3.6 | 40 | ||
2004-02-24 | 2003-12-31 | -9 | -9.0 | 0.0 | 0 | ||
2003-10-22 | 2003-09-30 | -10.8 | -5.4 | 5.4 | 50 | ||
2003-02-26 | 2002-12-31 | -12.6 | -10.8 | 1.8 | 14 | ||
2002-10-23 | 2002-09-30 | -16.2 | -1.8 | 14.4 | 88 | ||
2002-07-24 | 2002-06-30 | -17.1 | -16.2 | 0.9 | 5 | ||
2002-04-24 | 2002-03-31 | -18 | -14.4 | 3.6 | 20 | ||
2002-02-26 | 2001-12-31 | -20.4 | -19.8 | 0.6 | 2 | ||
2001-10-25 | 2001-09-30 | -23.4 | -19.8 | 3.6 | 15 | ||
2001-08-02 | 2001-06-30 | -22.8 | -18.0 | 4.8 | 21 | ||
2001-04-25 | 2001-03-31 | -16.2 | -12.6 | 3.6 | 22 | ||
2001-03-01 | 2000-12-31 | -13.5 | -14.4 | -0.9 | 6 | ||
2000-12-14 | 2000-09-30 | -9 | -9.0 | 0.0 | 0 | ||
2000-04-27 | 2000-03-31 | -10.8 | -7.2 | 3.6 | 33 | ||
1997-02-19 | 1996-12-31 | -18 | -16.2 | 1.8 | 10 | ||
1996-11-06 | 1996-09-30 | -18 | -18.0 | 0.0 | 0 | ||
1996-07-23 | 1996-06-30 | -18 | -39.6 | -21.6 | 120 | ||
1996-02-27 | 1995-12-31 | -25.2 | -28.8 | -3.6 | 14 | ||
1995-11-10 | 1995-09-30 | -27 | -32.4 | -5.4 | 20 | ||
1995-08-11 | 1995-06-30 | -25.2 | -27.0 | -1.8 | 7 | ||
1995-05-12 | 1995-03-31 | -23.4 | -25.2 | -1.8 | 7 | ||
1995-02-15 | 1994-12-31 | -35.1 | -19.8 | 15.3 | 43 | ||
1994-11-10 | 1994-09-30 | -24.3 | -23.4 | 0.9 | 3 | ||
1994-08-02 | 1994-06-30 | -25.2 | -23.4 | 1.8 | 7 | ||
1994-05-02 | 1994-03-31 | -25.2 | -19.8 | 5.4 | 21 | ||
1993-10-29 | 1993-09-30 | -21.6 | -27.0 | -5.4 | 25 | ||
1993-05-12 | 1993-03-31 | -18 | -23.4 | -5.4 | 30 |
Celldex Therapeutics Corporate Management
| Ronald Pepin | Chief Bus. Officer and Sr. VP | Profile | |
| Patrick Till | Senior Communications | Profile | |
| Prof Schlessinger | CoFounder Board | Profile | |
| Diane MD | Senior Officer | Profile | |
| Margo MD | Senior Affairs | Profile |
Additional Tools for Celldex Stock Analysis
When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.